Literature DB >> 19997745

Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet's disease.

Toshikatsu Kaburaki1, Fumiyuki Araki, Mitsuko Takamoto, Kimiko Okinaga, Atsushi Yoshida, Jiro Numaga, Yujiro Fujino, Hidetoshi Kawashima.   

Abstract

BACKGROUND: Recent publications have suggested considerable improvements in the clinical outcomes of ocular Behcet's disease (BD) patients. However, the long-term time course of clinical ocular features of BD in recent cases remains largely unknown. In this study, we investigated annual time-course changes of best-corrected visual acuity (BCVA) during ocular convalescent stages, as well as annual frequency of ocular attacks during the initial 10 years of follow-up in patients with BD.
METHODS: We studied 75 eyes in 39 patients (31 men, eight women) with BD, who were referred to our hospital between 1980 and 1996 within 1 year after the initial ocular attack and followed them up continuously for more than 10 years. The clinical courses of BCVA at the ocular convalescent stage from the onset of ocular disease were retrospectively examined, and the numbers of ocular attacks per eye per year were determined.
RESULTS: Mean BCVA was 0.59 at 1 year, 0.31 at 3 years, and 0.12 at 10 years from the onset of ocular disease, while the numbers of ocular attacks per eye were 4.1 +/- 3.1 at 1 year, 2.2 +/- 1.9 at 5 years, and 1.4 +/- 1.8 at 10 years. Ocular attacks were still observed in 33 eyes (45%) of 21 patients (54%) with BD even after 10 years. Final BCVA in 42 eyes (56%) became lower than 0.5. The major reasons for poor visual prognosis were macular atrophy (41%) and chorioretinal atrophy (26%).
CONCLUSIONS: The decline of BVCA continued, and nearly half the patients still suffered from ocular attacks at 10 years after the onset of ocular BD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19997745     DOI: 10.1007/s00417-009-1234-z

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  13 in total

Review 1.  Current concepts in the etiology and treatment of Behçet disease.

Authors:  Cem Evereklioglu
Journal:  Surv Ophthalmol       Date:  2005 Jul-Aug       Impact factor: 6.048

2.  Treatment and visual prognosis in Behçet's disease.

Authors:  D Benezra; E Cohen
Journal:  Br J Ophthalmol       Date:  1986-08       Impact factor: 4.638

3.  Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

Authors:  P P Sfikakis; P G Theodossiadis; C G Katsiari; P Kaklamanis; N N Markomichelakis
Journal:  Lancet       Date:  2001-07-28       Impact factor: 79.321

4.  Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement.

Authors:  Masaru Takeuchi; Hideyuki Hokama; Rintaroh Tsukahara; Takeshi Kezuka; Hiroshi Goto; Jun-Ichi Sakai; Masahiko Usui
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-06-28       Impact factor: 3.117

5.  Risk factor assessment and prognosis of eye involvement in Behcet's disease in Turkey.

Authors:  H Demiroğlu; I Barişta; S Dündar
Journal:  Ophthalmology       Date:  1997-04       Impact factor: 12.079

6.  Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.

Authors:  L Niccoli; C Nannini; M Benucci; D Chindamo; E Cassarà; C Salvarani; L Cimino; G Gini; I Lenzetti; F Cantini
Journal:  Rheumatology (Oxford)       Date:  2007-05-03       Impact factor: 7.580

7.  Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity.

Authors:  R Oktay Kaçmaz; John H Kempen; Craig Newcomb; Sapna Gangaputra; Ebenezer Daniel; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; Douglas A Jabs; C Stephen Foster
Journal:  Am J Ophthalmol       Date:  2008-08-16       Impact factor: 5.258

8.  Comparison of patients with Behçet's disease in the 1980s and 1990s.

Authors:  Atsushi Yoshida; Hidetoshi Kawashima; Yuta Motoyama; Hirobumi Shibui; Toshikatsu Kaburaki; Kazuyuki Shimizu; Kazuhiko Ando; Kiyono Hijikata; Yasuho Izawa; Kiyofumi Hayashi; Jiro Numaga; Yujiro Fujino; Kanjiro Masuda; Makoto Araie
Journal:  Ophthalmology       Date:  2004-04       Impact factor: 12.079

Review 9.  The eighth Frederick H. Verhoeff Lecture. presented by saiichi mishima, MD Behçet's disease in Japan: ophthalmologic aspects.

Authors:  S Mishima; K Masuda; Y Izawa; M Mochizuki; K Namba
Journal:  Trans Am Ophthalmol Soc       Date:  1979

10.  Uveitis in Behçet disease: an analysis of 880 patients.

Authors:  Ilknur Tugal-Tutkun; Sumru Onal; Rana Altan-Yaycioglu; Hasan Huseyin Altunbas; Meri Urgancioglu
Journal:  Am J Ophthalmol       Date:  2004-09       Impact factor: 5.258

View more
  9 in total

Review 1.  Improvement of neurological and ocular symptoms of Behçet's disease after the introduction of infliximab.

Authors:  Marko Barešić; Mirna Reihl; Mario Habek; Nenad Vukojević; Branimir Anić
Journal:  Rheumatol Int       Date:  2018-05-17       Impact factor: 2.631

2.  Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy.

Authors:  Atsushi Yoshida; Toshikatsu Kaburaki; Kimiko Okinaga; Mitsuko Takamoto; Hidetoshi Kawashima; Yujiro Fujino
Journal:  Jpn J Ophthalmol       Date:  2012-10-02       Impact factor: 2.447

3.  Long-term efficacy of infliximab on background vascular leakage in patients with Behçet's disease.

Authors:  H Keino; A A Okada; T Watanabe; W Taki
Journal:  Eye (Lond)       Date:  2014-06-20       Impact factor: 3.775

4.  Behçet's disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab.

Authors:  Toshikatsu Kaburaki; Kenichi Namba; Koh-hei Sonoda; Takeshi Kezuka; Hiroshi Keino; Takako Fukuhara; Koju Kamoi; Kei Nakai; Nobuhisa Mizuki; Nobuyuki Ohguro
Journal:  Jpn J Ophthalmol       Date:  2014-01-31       Impact factor: 2.447

5.  The Immunogenetics of Behcet's Disease.

Authors:  Mustafa Anıl Yılmaz; Ümit Türsen
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

6.  Clinical features of Behcet's disease in Mongolia: a multicenter study.

Authors:  Javzandulam Balt; Baasankhuu Jamyanjav; Sarantuya Jav; Zulgerel Dandii; Chimedlkhamsuren Ganbold; Yukihiro Horie; Anton Lennikov; Osamu Uehara; Shigeaki Ohno; Nobuyoshi Kitaichi
Journal:  Clin Rheumatol       Date:  2020-03-10       Impact factor: 2.980

Review 7.  Current and future treatments for Behçet's uveitis: road to remission.

Authors:  Marina Mesquida; Blanca Molins; Victor Llorenç; María Victoria Hernández; Gerard Espinosa; Andrew D Dick; Alfredo Adán
Journal:  Int Ophthalmol       Date:  2013-06-01       Impact factor: 2.031

8.  Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet's disease: a large-scale, long-term postmarketing surveillance in Japan.

Authors:  Shigeaki Ohno; Itsuro Umebayashi; Miyuki Matsukawa; Takashi Goto; Toshiro Yano
Journal:  Arthritis Res Ther       Date:  2019-01-05       Impact factor: 5.156

9.  Molecular Dynamics Simulation Reveals the Selective Binding of Human Leukocyte Antigen Alleles Associated with Behçet's Disease.

Authors:  Sirilak Kongkaew; Pathumwadee Yotmanee; Thanyada Rungrotmongkol; Nopporn Kaiyawet; Arthitaya Meeprasert; Toshikatsu Kaburaki; Hiroshi Noguchi; Fujio Takeuchi; Nawee Kungwan; Supot Hannongbua
Journal:  PLoS One       Date:  2015-09-02       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.